Brontictuzumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Notch 1 |
Clinical data | |
Other names | OMP-52M51 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6392H9862N1980O1710S50 |
Molar mass | 143410.36 g·mol−1 |
Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
It blocks the NOTCH1 receptor.[3]
This drug was developed by OncoMed Pharmaceuticals.
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ^ Cordo' V, van der Zwet JC, Canté-Barrett K, Pieters R, Meijerink JP (January 2021). "T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies". Blood Cancer Discovery. 2 (1): 19–31. doi:10.1158/2643-3230.BCD-20-0093. PMC 8447273. PMID 34661151.